Hint mode is switched on Switch off
For swift navigation between sections

Acura Pharmaceuticals
LEI 549300O2I06DTW1IM738

PDF download

Choose all Reset all
Download Cancel
Organization name
Acura Pharmaceuticals Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Acura Pharmaceuticals Inc is a pharmaceutical technology development company. The Company researches, develops, and manufactures active pharmaceutical ingredients (APIs) used as raw materials in the production of pharmaceutical products. Acura Pharmaceuticals has developed technologies for use in narcotic-based pain management products.

Awards

News

15/05/2025 Acura Pharmaceuticals: – Other Events
28/02/2025 Acura Pharmaceuticals: Entry Into A Material Definitive Agreement, – Completion Of Acquisition Or Disposition Of Assets, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Financial Statements And Exhibits
02/11/2024 Acura Pharmaceuticals: Entry Into A Material Definitive Agreement, – Completion Of Acquisition Or Disposition Of Assets, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Financial Statements And Exhibits
30/09/2024 Acura Pharmaceuticals: Entry Into A Material Definitive Agreement, – Completion Of Acquisition Or Disposition Of Assets, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Financial Statements And Exhibits
31/05/2024 Acura Pharmaceuticals: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers
All organization news

Documentation

IFRS/US GAAP reports

2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show more Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300O2I06DTW1IM738
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0000786947
Registration is required to get access.